This study evaluated the effect of the overexpression of IRF2BP2 in GC, indicating that IRF2BP2 regulated the expression of CTGF in a YAP1‐dependent manner and that the miR‐101‐3p‐IRF2BP2‐CTGF axis could be a potential prognostic marker and therapeutic target in GC. The gene discussed is IRF2BP2; the disease is gastric cancer.